Treatment of Chronic Pain With Cannabidiol (CBD) and Delta-9-tetrahydrocannabinol (THC)

• Status: Recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a study comparing the effects of Delta-9-Tetrahydrocannabinol (THC) versus Cannabidiol (CBD) versus a placebo on chronic non-cancer pain.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Utah
• Treatments: Cannabidiol; Dronabinol

Criteria

Inclusion criteria:

1. Age between 18-50 yrs.

2. History of cannabis use.

3. Chronic musculoskeletal and joint pain for at least 3 months or longer.

4. Participants must live within a 60 mile radius of Salt Lake City, Utah to be eligible.

Exclusion criteria:

1. Current or past neurological illness.

2. Substance abuse or dependence within the prior 60 days.

3. Contraindication to brain MRI.

4. Type I and type II diabetes.

5. Unstable medical conditions.

6. Consumption of more than 2 drinks of alcohol per night.

7. Current pregnancy or planning to become pregnant or breastfeeding

8. History of seizures or head trauma

9. Active or history of major mental illness

10. LFT results 3 times greater than the upper limit of normal at screening.

11. Participants may be excluded if the PI feels they do not meet safety criteria.